Geron Corp. (GERN)

1.36
NASDAQ : Health Technology
Prev Close 1.44
Day Low/High 1.35 / 1.46
52 Wk Low/High 0.95 / 6.99
Avg Volume 1.58M
Exchange NASDAQ
Shares Outstanding 188.42M
Market Cap 271.33M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Geron Announces Conference Call To Discuss Second Quarter Financial Results And Highlights

Geron Announces Conference Call To Discuss Second Quarter Financial Results And Highlights

Geron Corporation (Nasdaq:GERN) will announce its financial results for the second quarter ended June 30, 2011 on Thursday, July 28, 2011, after the closing of the equity market.

10 Stocks to Watch: Ixia, SemiLEDs

10 Stocks to Watch: Ixia, SemiLEDs

Ixia lowers its outlook for the fiscal second quarter.

'Mad Money Lightning Round': Grab Schlumberger

'Mad Money Lightning Round': Grab Schlumberger

Cramer's eager to own the stock at the current price level.

Geron Stock Hits New 52-Week Low (GERN)

Geron Stock Hits New 52-Week Low (GERN)

Geron Corporation (Nasdaq:GERN) hit a new 52-week low Friday as it is currently trading at $4.18, below its previous 52-week high of $6.40 with 203,466 shares traded as of 10:27 a.m. ET. Average volume has been 1.5 million shares over the past 30 days.

Geron Presents Data From GRNOPC1 Trial At International Conferences On Spinal Cord Medicine And Rehabilitation

Geron Presents Data From GRNOPC1 Trial At International Conferences On Spinal Cord Medicine And Rehabilitation

Geron Corporation (Nasdaq: GERN) today announced two presentations on the company’s ongoing Phase 1 clinical trial of the human embryonic stem cell-based therapy, GRNOPC1, in patients with spinal cord injury.

Geron To Present At Jefferies 2011 Global Healthcare Conference

Geron To Present At Jefferies 2011 Global Healthcare Conference

Geron Corporation (Nasdaq: GERN) today announced that David L. Greenwood, President and Chief Executive Officer, will present a company update at 4:00 p.

Geron Highlights ASCO/AACR Joint Session: Telomeres And Telomerase In Cancer

Geron Highlights ASCO/AACR Joint Session: Telomeres And Telomerase In Cancer

Geron Corporation (Nasdaq: GERN) highlights presentations at the American Society of Clinical Oncology (ASCO)/American Association for Cancer Research (AACR) Joint Session: Telomeres and Telomerase in Cancer taking...

Geron Stock Hits New 52-Week Low (GERN)

Geron Stock Hits New 52-Week Low (GERN)

Geron Corporation (Nasdaq:GERN) hit a new 52-week low Wednesday as it is currently trading at $4.29, below its previous 52-week high of $6.40 with 1.2 million shares traded as of 3:32 p.m. ET. Average volume has been 1.5 million shares over the past 30 days.

Geron Stock Hits New 52-Week Low (GERN)

Geron Stock Hits New 52-Week Low (GERN)

Geron Corporation (Nasdaq:GERN) hit a new 52-week low Tuesday as it is currently trading at $4.36, below its previous 52-week high of $6.40 with 1.2 million shares traded as of 11:52 a.m. ET. Average volume has been 1.5 million shares over the past 30 days.

Geron Announces Senior Management Appointments

Geron Announces Senior Management Appointments

Geron Corporation (Nasdaq:GERN) today announced the appointments of Stephen Kelsey, M.

Http://www.nmh.org/nm/home (Graphic: Business Wire)

Http://www.nmh.org/nm/home (Graphic: Business Wire)

Researchers at Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine and The Rehabilitation Institute of Chicago (RIC) recently enrolled their first subject in a national...

Geron Statement Regarding European Cancer Vaccine Patents

Geron Statement Regarding European Cancer Vaccine Patents

Geron Corporation (Nasdaq: GERN) today commented on a ruling from the European Patent Office (EPO) with regard to its European patent 084139, and the issuance of a second Geron patent covering telomerase peptides, ...

Geron Announces $25 Million In Funding From California Institute Of Regenerative Medicine

Geron Announces $25 Million In Funding From California Institute Of Regenerative Medicine

Geron Corporation (Nasdaq: GERN) today announced that the company has been approved to receive a Targeted Clinical Development Award totaling $25 million from the California Institute for Regenerative Medicine (CIRM).

Geron Corporation Reports 2011 First Quarter Financial Results And Highlights

Geron Corporation Reports 2011 First Quarter Financial Results And Highlights

Geron Corporation (Nasdaq: GERN) today reported financial results for the three months ended March 31, 2011.

Geron Announces Conference Call To Discuss First Quarter Financial Results And Highlights

Geron Announces Conference Call To Discuss First Quarter Financial Results And Highlights

Geron Corporation (Nasdaq: GERN) will announce its financial results for the first quarter ended March 31, 2011 on Wednesday, April 27, 2011, after the closing of the equity market.

Geron Announces The Appointment Of Melanie Nallicheri As Senior Vice President Of Corporate Development For Cell Therapies

Geron Announces The Appointment Of Melanie Nallicheri As Senior Vice President Of Corporate Development For Cell Therapies

Geron Corporation (Nasdaq:GERN) today announced the appointment of Melanie I.

Geron To Webcast Analyst And Investor Meeting On Company’s Cell Therapy Programs On April 19, 2011

Geron To Webcast Analyst And Investor Meeting On Company’s Cell Therapy Programs On April 19, 2011

Geron Corporation (NASDAQ:GERN) today announced that it will host a live webcast of the analyst and investor meeting on its cell therapy programs being held in New York from 12:15 p.

Geron To Webcast Analyst And Investor Meeting On Company’s Oncology Programs On March 29, 2011

Geron To Webcast Analyst And Investor Meeting On Company’s Oncology Programs On March 29, 2011

Geron Corporation (NASDAQ:GERN) today announced that it will host a live webcast of the analyst and investor meeting on its oncology programs being held in New York from 12:15 p.

Geron Announces Preclinical Study Data Of GRNCM1

Geron Announces Preclinical Study Data Of GRNCM1

Geron Corporation (Nasdaq:GERN) today announced preclinical study data showing positive effects of GRNCM1, Geron's cardiomyocyte product derived from human embryonic stem cells (hESCs), in a small animal model of acute...

Geron Corporation Reports Fourth Quarter And Annual 2010 Financial Results

Geron Corporation Reports Fourth Quarter And Annual 2010 Financial Results

Geron Corporation (Nasdaq: GERN) today reported financial results for the fourth quarter and year ended December 31, 2010.

Geron Announces Conference Call To Discuss Fourth Quarter And Annual 2010 Financial Results And Highlights

Geron Announces Conference Call To Discuss Fourth Quarter And Annual 2010 Financial Results And Highlights

Geron Corporation (Nasdaq: GERN) will announce its financial results for the fourth quarter and year ended December 31, 2010 on Thursday, February 24, 2011, after the closing of the equity market.

Geron To Present At 13th Annual BIO CEO & Investor Conference

Geron To Present At 13th Annual BIO CEO & Investor Conference

Geron Corporation (NASDAQ:GERN) today announced that David L. Greenwood, president and chief executive officer, will present an update of the company at 11:30 a.

Geron Appoints David Greenwood President, Interim CEO And Director

Geron Appoints David Greenwood President, Interim CEO And Director

Geron Corporation (Nasdaq:GERN) today announced a new leadership structure that reflects the company’s progression into mid-stage clinical development of multiple therapeutic product candidates.

Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Geron Corporation

Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Geron Corporation

Ryan & Maniskas, LLP ( www.rmclasslaw.

Geron Initiates Phase 2 Clinical Trial Of Imetelstat In Essential Thrombocythemia

Geron Initiates Phase 2 Clinical Trial Of Imetelstat In Essential Thrombocythemia

Geron Corporation (NASDAQ:GERN) today announced enrollment of the first patient in a Phase 2 clinical trial to evaluate the activity of the company’s telomerase inhibitor drug, imetelstat (GRN163L), in patients ...

Holzer Holzer & Fistel, LLC Announces Investigation Into Potential Claims For Breach Of Fiduciary Duties By Certain Officers And Directors Of Geron Corporation

Holzer Holzer & Fistel, LLC Announces Investigation Into Potential Claims For Breach Of Fiduciary Duties By Certain Officers And Directors Of Geron Corporation

Holzer Holzer & Fistel, LLC announces that it is investigating potential breaches of fiduciary duties by certain officers and directors of Geron Corporation (“Geron” or the “Company”) (NASDAQ:...

Geron Announces Publication Demonstrating Activity Of Imetelstat Against Cancer Stem Cells From Pediatric Neural Tumors

Geron Announces Publication Demonstrating Activity Of Imetelstat Against Cancer Stem Cells From Pediatric Neural Tumors

Geron Corporation (Nasdaq:GERN) today announced the publication of preclinical data demonstrating that the company’s telomerase inhibitor drug, imetelstat (GRN163L), currently in Phase 2 clinical trials, ...

Geron To Present At J.P. Morgan Annual Healthcare Conference

Geron To Present At J.P. Morgan Annual Healthcare Conference

Geron Corporation (Nasdaq:GERN) today announced that Thomas B. Okarma, Ph.

Shareholder Claims Against Geron Corporation Investigated By Goldfarb Branham LLP

Shareholder Claims Against Geron Corporation Investigated By Goldfarb Branham LLP

Goldfarb Branham LLP is investigating whether certain officers and directors of Geron Corporation, Inc.

Hagens Berman Investigates Geron Corporation For Securities Violations

Hagens Berman Investigates Geron Corporation For Securities Violations

Hagens Berman is investigating Geron Corp. (NASDAQ:GERN) on behalf of investors after a lawsuit claims the biopharmaceuticals company violated the Securities Exchange Act of 1934.

TheStreet Quant Rating: D (Sell)